Literature DB >> 17875749

Targeted agents: the rules of combination.

Eunice L Kwak1, Jeffrey W Clark, Bruce Chabner.   

Abstract

The success of molecularly targeted agents (MTA) in the treatment of cancer has led to the investigation of their use in combination with other MTAs and with conventional chemotherapies. An overview of the MTAs that have emerged as Food and Drug Administration-approved drugs is presented, along with a framework for the consideration of how MTAs can best be combined to maximize therapeutic effect.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17875749     DOI： 10.1158/1078-0432.CCR-07-1385

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  27 in total

Review 1.  Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements.

Authors:  Shivanni Kummar; Helen X Chen; John Wright; Susan Holbeck; Myrtle Davis Millin; Joseph Tomaszewski; James Zweibel; Jerry Collins; James H Doroshow
Journal:  Nat Rev Drug Discov       Date:  2010-10-29       Impact factor: 84.694

2.  Disrupting the networks of cancer.

Authors:  Daniel F Camacho; Kenneth J Pienta
Journal:  Clin Cancer Res       Date:  2012-03-22       Impact factor: 12.531

Review 3.  Potential synergies for combined targeted therapy in the treatment of neuroendocrine cancer.

Authors:  Ramon Salazar; Diane Reidy-Lagunes; James Yao
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

4.  Opportunities and challenges in the development of experimental drug combinations for cancer.

Authors:  Rachel W Humphrey; Laura M Brockway-Lunardi; David T Bonk; Kathleen M Dohoney; James H Doroshow; Sandra J Meech; Mark J Ratain; Suzanne L Topalian; Drew M Pardoll
Journal:  J Natl Cancer Inst       Date:  2011-07-15       Impact factor: 13.506

5.  Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours.

Authors:  V Gregorc; A Santoro; E Bennicelli; C J A Punt; G Citterio; J N H Timmer-Bonte; F Caligaris Cappio; A Lambiase; C Bordignon; C M L van Herpen
Journal:  Br J Cancer       Date:  2009-06-30       Impact factor: 7.640

6.  Melanoma: a model for testing new agents in combination therapies.

Authors:  Paolo A Ascierto; Howard Z Streicher; Mario Sznol
Journal:  J Transl Med       Date:  2010-04-20       Impact factor: 5.531

Review 7.  Personalized therapies in the cancer "omics" era.

Authors:  Alberto Ocaña; Atanasio Pandiella
Journal:  Mol Cancer       Date:  2010-07-29       Impact factor: 27.401

8.  Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma.

Authors:  Devin G Roller; Mark Axelrod; Brian J Capaldo; Karin Jensen; Aaron Mackey; Michael J Weber; Daniel Gioeli
Journal:  Mol Cancer Ther       Date:  2012-09-07       Impact factor: 6.261

9.  Systemic delivery of a Gli inhibitor via polymeric nanocarriers inhibits tumor-induced bone disease.

Authors:  Joseph P Vanderburgh; Kristin A Kwakwa; Thomas A Werfel; Alyssa R Merkel; Mukesh K Gupta; Rachelle W Johnson; Scott A Guelcher; Craig L Duvall; Julie A Rhoades
Journal:  J Control Release       Date:  2019-09-05       Impact factor: 9.776

10.  Oncology drug development and approval of systemic anticancer therapy by the U.S. Food and Drug Administration.

Authors:  Robert E Martell; David Sermer; Kenneth Getz; Kenneth I Kaitin
Journal:  Oncologist       Date:  2012-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.